ACZ885: A Robust Treatment Option for Reducing Cardiovascular Risk?
On August 27, 2017, Novartis (NVS) announced positive results from its Phase 3 trial, CANTOS.
Novartis’s (NVS) Gilenya reported sales of $825 .0 million in 4Q17, which is a year-over-year (or YoY) drop of 1.0%.
Novartis (NVS) plans to submit to an FDA application seeking regulatory approval for investigational drug RTH258.
Last week, the state of Pennsylvania saw some of its first few medical marijuana (MJX) dispensaries opening doors to patients suffering from one of 17 “serious medical conditions.”
Last week, the province of Manitoba announced four private consortiums and companies to retail marijuana in the province.
While marijuana stocks (MJX) ended in the negative territory week-over-week last week, two new marijuana sector-specific ETFs debuted.
Privately held grocery chain Albertsons Companies announced its merger with drugstore chain Rite Aid (RAD) on February 20, 2018.
Analysts’ recommendations for GSK show a 12-month target price of $40.50 per share compared to its price of $36.46 per share on February 14.
On February 15, 2018, GlaxoSmithKline traded at a forward PE multiple of 12.9x, which is lower than the industry average of 13.3x.
GSK’s Consumer Healthcare business reported revenues of ~1.9 billion pounds in 4Q17, reflecting ~1.0% growth in revenues in 4Q16.
GlaxoSmithKline’s (GSK) Vaccines business reported revenues of ~1.2 billion pounds during 4Q17, for ~6.0% growth compared to 4Q16.
Benlysta’s sales increased ~10.0% to ~97.0 million pounds in 4Q17, including ~15.0% growth in revenues at constant exchange rates.
GSK’s HIV products reported revenues of ~1.2 billion pounds in 4Q17, for ~13.0% growth compared to 4Q16.
GlaxoSmithKline’s (GSK) Europe market reported ~1.0% growth in revenues to ~1.0 billion pounds in 4Q17.
GSK’s Pharmaceuticals segment reported revenues of ~4.5 billion pounds during 4Q17, an ~1.0% decrease in revenues compared to 4Q16.
GlaxoSmithKline (GSK) reported revenues of 7.64 billion pounds in 4Q17, reflecting 1.0% growth compared to 7.59 billion pounds in 4Q16.
Despite its robust efficacy profile, Aimovig has shown a safety and tolerability profile similar to that of a placebo.
Aimovig, which is Novartis’s (NVS) investigational migraine prophylaxis therapy, is under review by the FDA and the European Medicines Agency.
Lutathera and SEG101 are expected to significantly strengthen Novartis’s position in the oncology segment.
Jakavi reported sales of $228.0 million in 4Q17, which is a year-over-year rise of 33.0% on a constant currency basis.